RenovoRx Inc. (RNXT)
NASDAQ (CM) NASDAQ (CM) Primary Summary
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago.
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
RenovoRx (RNXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.
RenovoRx Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SR Swayampakula Ramakanth HC Wainwright & Co. | 63,073.93 | $58,474.64 | $52,982.1 | -$5,492.54 | -9.39% |
| EW Edward Woo Ascendiant Capital | 36,388.49 | $30,955.69 | $30,566.33 | -$389.36 | -1.26% |
RenovoRx Inc. (RNXT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has RenovoRx Inc. ever had a stock split?
RenovoRx Inc. Profile
| Biotechnology Industry | Healthcare Sector | Shaun R. Bagai CEO | NASDAQ (CM) Exchange | 75989R107 CUSIP |
| US Country | 10 Employees | - Last Dividend | - Last Split | 26 Aug 2021 IPO Date |
Overview
RenovoRx, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies aimed at treating solid tumors. Established in 2009, the company combines its expertise in drug development and medical device technology to create targeted treatments that address the complex challenges of cancer therapy. Headquartered in Los Altos, California, RenovoRx is at the forefront of advancing cancer treatment modalities through its strategic research collaborations and its commitment to improving patient outcomes in the fight against cancer.
Products and Services
- RenovoGem:
This leading product candidate epitomizes the innovative approach of RenovoRx to cancer treatment. RenovoGem is a pioneering drug and device combination that marries intra-arterial gemcitabine with the RenovoCath delivery system. Currently, in Phase III clinical trials, RenovoGem targets locally advanced pancreatic cancer with a direct approach intended to maximize therapeutic efficacy while minimizing systemic side effects. This targeted treatment paradigm exemplifies the company's dedication to enhancing the precision and effectiveness of cancer therapies.
- Research Collaboration with Imugene Limited:
In its mission to expand the horizons of cancer therapy, RenovoRx has engaged in a significant research collaboration with Imugene Limited. This partnership focuses on leveraging oncolytic virus therapy as a novel strategy to treat difficult-to-access tumors. Oncolytic viruses represent a cutting-edge approach in oncology, utilizing genetically modified viruses to selectively infect and destroy cancer cells. Through this collaboration, RenovoRx aims to explore the potential of these biological agents to revolutionize the treatment landscape for tumors that are challenging to treat with conventional methods.
